



Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents

Diabetes Care 2017;40:1034–1040 | <https://doi.org/10.2337/dc16-2508>

Maria E. Craig,^{1,2,3} Nicole Prinz,^{4,5} Claire T. Boyle,⁶ Fiona M. Campbell,⁷ Timothy W. Jones,^{8,9} Sabine E. Hofer,¹⁰ Jill H. Simmons,¹¹ Naomi Holman,¹² Elaine Tham,¹³ Elke Fröhlich-Reiterer,¹⁴ Stephanie DuBose,⁶ Helen Thornton,¹⁵ Bruce King,¹⁶ David M. Maahs,¹⁷ Reinhard W. Holl,^{4,5} and Justin T. Warner,¹⁸ on behalf of the Australasian Diabetes Data Network (ADDN), the T1D Exchange Clinic Network (T1DX), the National Paediatric Diabetes Audit (NPDA) and the Royal College of Paediatrics and Child Health, and the Prospective Diabetes Follow-up Registry (DPV) initiative*

Downloaded from <http://diabetesjournals.org/care/article-pdf/40/8/1034/553365/doi162508.pdf> by guest on 02 June 2023

OBJECTIVE

Celiac disease (CD) has a recognized association with type 1 diabetes. We examined international differences in CD prevalence and clinical characteristics of youth with coexisting type 1 diabetes and CD versus type 1 diabetes only.

RESEARCH DESIGN AND METHODS

Data sources were as follows: the Prospective Diabetes Follow-up Registry (DPV) (Germany/Austria); the T1D Exchange Clinic Network (T1DX) (U.S.); the National Paediatric Diabetes Audit (NPDA) (U.K. [England/Wales]); and the Australasian Diabetes Data Network (ADDN) (Australia). The analysis included 52,721 youths <18 years of age with a clinic visit between April 2013 and March 2014. Multivariable linear and logistic regression models were constructed to analyze the relationship between outcomes (HbA_{1c}, height SD score [SDS], overweight/obesity) and type 1 diabetes/CD versus type 1 diabetes, adjusting for sex, age, and diabetes duration.

RESULTS

Biopsy-confirmed CD was present in 1,835 youths (3.5%) and was diagnosed at a median age of 8.1 years (interquartile range 5.3–11.2 years). Diabetes duration at CD diagnosis was <1 year in 37% of youths, >1–2 years in 18% of youths, >3–5 years in 23% of youths, and >5 years in 17% of youths. CD prevalence ranged from 1.9% in the T1DX to 7.7% in the ADDN and was higher in girls than boys (4.3% vs. 2.7%, $P < 0.001$). Children with coexisting CD were younger at diabetes diagnosis compared with those with type 1 diabetes only (5.4 vs. 7.0 years of age, $P < 0.001$) and fewer were non-white (15 vs. 18%, $P < 0.001$). Height SDS was lower in those with CD (0.36 vs. 0.48, adjusted $P < 0.001$) and fewer were overweight/obese (34 vs. 37%, adjusted $P < 0.001$), whereas mean HbA_{1c} values were comparable: $8.3 \pm 1.5\%$ (67 ± 17 mmol/mol) versus $8.4 \pm 1.6\%$ (68 ± 17 mmol/mol).

CONCLUSIONS

CD is a common comorbidity in youth with type 1 diabetes. Differences in CD prevalence may reflect international variation in screening and diagnostic practices, and/or CD risk. Although glycemic control was not different, the lower height SDS supports close monitoring of growth and nutrition in this population.

¹The Children's Hospital at Westmead, Sydney, New South Wales, Australia

²University of New South Wales, Sydney, New South Wales, Australia

³Charles Perkins Centre Westmead, University of Sydney, Sydney, New South Wales, Australia

⁴Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany

⁵German Center for Diabetes Research, Munich-Neuherberg, Germany

⁶Jaeb Center for Health Research, Tampa, FL

⁷Leeds Children's Hospital, Leeds, U.K.

⁸The University of Western Australia, Perth, Western Australia, Australia

⁹Telethon Kids Institute, Perth, Australia

¹⁰Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria

¹¹Vanderbilt University Medical Center, Nashville, TN

¹²Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K.

¹³Women's and Children's Hospital, Adelaide, South Australia, Australia

¹⁴Department of Pediatrics, Medical University of Graz, Graz, Austria

¹⁵St. Helens and Knowsley Teaching Hospitals NHS Trust, St. Helens, U.K.

¹⁶John Hunter Children's Hospital, Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia

¹⁷Lucile Salter Packard Children's Hospital Stanford, Stanford University Medical Center, Palo Alto, CA

¹⁸Children's Hospital for Wales, Cardiff, U.K.

The prevalence of celiac disease (CD) is higher in patients with type 1 diabetes compared with the general population (~5% vs. 1%) (1,2). However, case detection is likely to reflect screening practices within the type 1 diabetes population (3) and in at-risk cohorts (4), since the majority of case patients are asymptomatic at diagnosis. There is some evidence for a greater risk in association with type 1 diabetes diagnosed before the age of 5 years and European heritage (1). Conflicting data exist as to whether the risk of CD is higher in females or males with type 1 diabetes (1), which is in contrast to the general population where no sex bias is observed in children but there is a female sex bias in adults (5).

The burden of coexisting CD and type 1 diabetes may be expected to negatively impact glycemic control, although existing data are conflicting. Although several studies have shown no difference in glycemic control among people with type 1 diabetes, with or without CD (6–8), the HbA_{1c} level was lower in adolescents with both conditions, except in those who did not adhere to the gluten-free diet (9).

There are no multinational studies that have systematically compared clinical characteristics and treatment between youths with coexisting CD and type 1 diabetes and youths with type 1 diabetes only. We therefore analyzed registry and audit data from the following four large databases across three continents: the Prospective Diabetes Follow-up Registry (DPV) in Germany and Austria; the National Pediatric Diabetes Audit (NPDA) in the U.K. (England and Wales); the T1D Exchange Clinic Network (T1DX) in the U.S.; and the Australasian Diabetes Data Network (ADDN). These registries record data on the screening and diagnosis of CD, along with clinical and demographic data and therapy. Our aim was to examine international differences in prevalence and management to improve our understanding of the impact of both conditions.

RESEARCH DESIGN AND METHODS

Participants

This analysis included 52,721 participants <18 years of age with a diagnosis

of type 1 diabetes, who had made at least one clinic visit between 1 April 2013 and 31 March 2014. The characteristics and methods of each of the four participating registries are described below.

DPV

The DPV is a prospective longitudinal standardized computer-based documentation system for demographics, medical care, and outcome of patients with all diabetes types (www.d-p-v.eu) (10). Currently, >90% of German and >80% of Austrian children with diabetes, from 442 centers, are included in the registry. Since 1995, data have been documented locally by the participating centers in an electronic health record. Twice yearly, anonymized data are exported and transmitted for central analyses and external quality assurance. Missing and inconsistent data are reported back to the centers for correction. Data collection is approved by the ethics committee at Ulm University and by the institutional review boards (IRBs) at the participating centers (11).

NPDA

The NPDA collects data on outcomes and care processes for children and young people in whom diabetes has been diagnosed who attend pediatric diabetes units (PDUs) in the U.K. (in England and Wales) (<http://www.rcpch.ac.uk/npda>) (12). Each PDU submits data annually to the NPDA. A total of 177 PDUs from England and Wales submitted data during the study period. The Royal College of Pediatrics and Child Health, which delivers the NPDA, has ethical approval to collect and hold patient information for the NPDA without written consent. However, patients and their parents are informed of the submission of their data to the NPDA by the local PDUs. Data were pseudonymized for the purposes of this study.

T1DX

The T1DX includes 77 U.S.-based pediatric and adult endocrinology practices in 35 states. This registry of >30,000 individuals with type 1 diabetes commenced enrollment in September 2010 (13). Each clinic received approval from a local IRB.

Informed consent was obtained according to IRB requirements. Data were collected for the central database of the registry from the participant's medical record and by having the participant or the participant's parent complete a comprehensive questionnaire, as previously described (14). This analysis included youth <18 years of age from the 52 registry sites caring for pediatric patients. All participating centers are listed at <https://t1dexchange.org/pages/resources/clinic-network/#4/37.16/-96.33>.

ADDN

The ADDN is a longitudinal centralized, standardized data collection system for patients with all diabetes types, which commenced enrollment in 2012 (15). Data are documented locally by the participating centers in an electronic database, and anonymized data are transferred twice yearly to the central database. Missing and inconsistent data are reported back to the centers for correction. Currently, the database contains longitudinal data on >5,000 children and adolescents with diabetes from five sites in Australia (16). Each participating center received approval from its local IRB, and informed consent was obtained according to IRB requirements.

Study Measures

The main study measure was the rate of CD among participants with type 1 diabetes. Screening for CD was performed according to local practices, in keeping with the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines, which recommend screening at the time of diabetes diagnosis and every 1–2 years thereafter (17). CD was defined based on biopsy-proven results, in keeping with past and recent ISPAD guidelines (17,18). "Suspected CD" was defined as a positive CD screening result without small bowel biopsy.

Individual mean HbA_{1c} values over the year of the registry assessment were used to represent HbA_{1c} in this analysis. HbA_{1c} values were standardized using values from the Diabetes Control and

Received 1 December 2016 and accepted 23 April 2017.

Corresponding author: Maria E. Craig, m.craig@unsw.edu.au.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-2508/-/DC1>.

M.E.C. and N.P. are co-first authors.

R.W.H. and J.T.W. are co-senior authors.

*A listing of information for the ADDN, the T1DX, the NPDA, and the DPV initiative can be found in the Supplementary Data online.

© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

Complications Trial (DCCT) (19). Any use of a pump during the observation period was categorized as pump use; otherwise, patients were categorized as using injections. BMI was calculated from height and weight; z scores for height and BMI, adjusted for age and sex, were computed using the World Health Organization (WHO) reference tables (20,21). Overweight and obesity were defined according to the WHO as BMI z scores >1 SD and 2 SDs, respectively (21). Severe hypoglycemia was defined as an event in which the participant experienced a seizure or loss of consciousness.

Ethnic minority status for the DPV was defined as at least one parent born outside of Germany or Austria (positive migration history). Ethnicity data for England and Wales was reported to the NPDA by the participating center. This is a self-reported ethnicity by the patient and the patient's family using a list of contemporary ethnic categories (white, black, Asian, mixed, other, or not stated). Minority status was defined as nonwhite, with "not stated" being excluded as missing data. For the T1DX, ethnic minority status was defined as other than non-Hispanic white. For the ADDN, ethnicity was defined according to the Australian Standard Classification of Cultural and Ethnic Groups (22), and ethnic minority status was defined as other than white.

Statistical Analysis

Summary statistics were calculated overall, within registries, and by the presence or absence of CD. For continuous variables results are reported as the median (interquartile range) or mean \pm SD for HbA_{1c} and for dichotomous variables as the percentage. A Kruskal-Wallis or χ^2 test was performed to compare demographic and clinical characteristics between registries and by the presence or absence of CD.

Linear regression was performed to assess the relationship between the presence of CD and continuous variables (HbA_{1c}, height SD score [SDS], BMI SDS, insulin dose per kilogram of body weight), with models adjusted for sex, age, and duration of diabetes. For insulin dose as an outcome, models were also adjusted for insulin pump therapy. For HbA_{1c} as an outcome, additional models were constructed adjusting for ethnicity (minority vs. nonminority) or the interaction between ethnicity and CD. Logistic regression was performed to assess the relationship between the presence of CD and categorical variables (HbA_{1c} $<7.5\%$ or $>9.0\%$; insulin pump therapy; severe hypoglycemia), with models adjusted for sex, age, and duration of diabetes. For pump therapy and severe hypoglycemia outcomes, additional models were constructed adjusting for ethnicity or ethnicity/CD interaction.

All statistical analyses were performed using SAS version 9.4 software (SAS Institute, Inc., Cary, NC). A priori, in view of the large sample size and multiple comparisons, only *P* values <0.01 were considered to be statistically significant.

RESULTS

Clinical characteristics including age at diabetes diagnosis and age at visit were similar across the four registries despite statistical significance due to the large sample size (Table 1). Median diabetes duration ranged from 3.8 years in the DPV to 6.0 years in the T1DX. Ethnic minority status ranged from 12.2% in the NPDA to 31.7% in the ADDN. Median height SDS was 0.47, and median BMI SDS was 0.67, indicating that participants overall were heavier and taller compared with reference standards. The proportion of overweight/obesity was highest in the T1DX (44%) and lowest in the DPV (33%). Mean HbA_{1c} was lowest in the DPV (7.9% [63 mmol/mol]) and highest in the NPDA (8.9% [74 mmol/mol]). The DPV, T1DX, and ADDN had higher rates of pump use (43.0%, 60.5%, and 40.1%, respectively) compared with the NPDA (17.7%), Table 1.

Biopsy-proven CD was present in 1,835 participants (3.5%), with a higher prevalence in girls than in boys (4.3 vs. 2.7%, *P* < 0.001) and in those ≤ 5 years of age at diabetes diagnosis (4.8%

Table 1—Descriptive characteristics of patients overall and by registry

	Overall (N = 52,721)	DPV (n = 24,611)	T1DX (n = 7,536)	NPDA (n = 17,152)	ADDN (n = 3,422)	<i>P</i> value
Male	52.3	52.5	52.1	52.1	51.7	0.692
Age at visit (years)	13.2 [10.0–15.7]	12.8 [9.4–15.4]	13.0 [10.0–15.0]	14.1 [11.0–16.2]	12.9 [9.6–15.3]	<0.001
Age at diabetes diagnosis (years)	7.0 [4.0–10.2]	7.3 [4.2–10.6]	6.0 [3.0–9.0]	7.0 [3.8–10.1]	6.9 [4.0–10.1]	<0.001
Diabetes duration at visit (years)	4.9 [2.6–7.9]	3.8 [1.5–7.0]	6.0 [3.0–8.0]	5.7 [3.6–8.6]	4.3 [1.9–7.5]	<0.001
Ethnic minority	18.2	20.4	20.9	12.2	31.7	<0.001
Height SDS WHO	0.47 [−0.23 to 1.18]	0.58 [−0.10 to 1.26]	0.48 [−0.24 to 1.24]	0.30 [−0.41 to 1.01]	0.47 [−0.22 to 1.15]	<0.001
BMI SDS WHO	0.67 [−0.01 to 1.36]	0.57 [−0.11–1.25]	0.86 [0.24–1.53]	0.71 [0.01–1.39]	0.82 [0.13–1.49]	<0.001
Overweight/obese	37.0	33.1	44.2	38.6	42.5	<0.001
Mean HbA _{1c}						
%	8.4 \pm 1.6	7.9 \pm 1.5	8.7 \pm 1.5	8.9 \pm 1.6	8.2 \pm 1.4	<0.001
mmol/mol	67.9 \pm 17.5	62.8 \pm 16.8	71.3 \pm 16.5	73.8 \pm 17.0	66.6 \pm 15.3	<0.001
HbA _{1c}						
$<7.5\%$ (58 mmol/mol)	30.5	45.8	18.0	14.3	29.1	<0.001
$>9.0\%$ (75 mmol/mol)	26.4	17.0	30.5	39.0	22.1	<0.001
Insulin pump therapy	37.0	43.0	60.5	17.7	40.1	<0.001

Data are reported as percentages, median [interquartile range], or mean \pm SD.

vs. 2.8%, $P < 0.001$). The ADDN had the highest prevalence of CD (7.7%) followed by the NPDA (3.8%), DPV (3.2%), and T1DX (1.9%). An additional 2% of patients (from the DPV and T1DX only) had a positive CD screen result without small bowel biopsy. The median age at diabetes diagnosis was younger in those participants with coexisting CD compared with those with type 1 diabetes alone (5.4 vs. 7.0 years of age, $P < 0.001$) (Table 2). Among participants with CD, the proportion from an ethnic minority group was lower overall compared with type 1 diabetes alone (15% vs. 18%, $P = 0.001$) in the T1DX ($P = 0.002$) and ADDN ($P = 0.002$) but not in the NPDA ($P = 0.04$) or DPV ($P = 0.53$). Youth with coexisting CD had a slightly lower height SDS (0.36 vs. 0.48, adjusted $P < 0.001$), after adjusting for age, sex, and diabetes duration (Table 2); the adjusted difference in height SDS was also significantly lower in the DPV ($P < 0.001$) and NPDA ($P = 0.003$) but not in the T1DX ($P = 0.06$) or ADDN ($P = 0.47$). When stratified by ethnic minority status, height SDS was lowest in nonwhite youth with CD compared with white youth without CD (0.17 vs. 0.50). The difference in BMI SDS overall (0.61 vs. 0.67, adjusted $P = 0.006$) was not clinically important, and the differences were not statistically significant across the individual registries after adjustment for age, sex, and diabetes

duration. When stratified by ethnic minority status, BMI SDS was lowest in white youth with CD versus ethnic minority youth without CD (0.51 vs. 0.68, adjusted $P < 0.001$). The proportion of overweight/obesity was slightly lower overall for those with coexisting CD compared with type 1 diabetes alone (34% vs. 37%, adjusted $P < 0.001$) and in the DPV (27% vs. 33%, adjusted $P < 0.001$) but not in the other registries.

The characteristics of participants with CD by registry are shown in Table 3. Overall, CD was diagnosed in 5.4% of patients before the diagnosis of type 1 diabetes, in 37% of patients with diabetes duration of <1 year, in 18% of patients during year 2 of diabetes, in 23% of patients during years 3–5 of diabetes, and in 17% of patients after >5 years of diabetes. Despite differences in the rates of CD across registries, the median age at the diagnosis of CD was very similar (~ 8 years). HbA_{1c} and the proportion of patients with HbA_{1c} levels $<7.5\%$ or $>9.0\%$ did not differ clinically overall between those with coexisting type 1 diabetes and CD and those with type 1 diabetes alone (Table 2) or within individual registries when adjusted for age, sex, and duration of diabetes, with the exception of the DPV where the difference was statistically significant but not clinically important (7.8% vs. 7.9%, $P = 0.007$). In the multivariable linear

regression model, HbA_{1c} level was slightly higher in ethnic minority youth with type 1 diabetes alone (8.5% vs. 8.3%, adjusted $P < 0.001$) but did not differ between ethnicities among youth with type 1 diabetes and comorbid CD (8.3% vs. 8.3%, adjusted $P = 0.42$).

The proportion of patients treated with insulin pumps was significantly higher in those with CD in the T1DX (75% vs. 60%, adjusted $P = 0.003$) but did not differ overall (adjusted $P = 0.41$) or within the other registries. Among youth with CD, the proportion treated with continuous subcutaneous insulin infusion was lower for those of ethnicity minority status compared with white ethnicity (33% vs. 43%, adjusted $P < 0.001$); a lower rate of pump therapy was also observed in those with type 1 diabetes alone (nonwhite vs. white ethnicity 33% vs. 39%, adjusted $P < 0.001$). The insulin dose per kilogram of body weight was not clinically different in those with versus those without CD (0.80 vs. 0.82 units/kg/day, adjusted $P = 0.025$) (Table 2), and differences approached statistical significance for the DPV (0.78 vs. 0.80 units/kg/day, $P = 0.018$) and T1DX (0.78 vs. 0.85, $P = 0.05$).

CONCLUSIONS

This analysis from four international registries spanning three continents demonstrates that CD is common in children

Table 2—Characteristics of patients with type 1 diabetes with or without CD

	CD and type 1 diabetes (n = 1,835)	Type 1 diabetes (n = 50,886)	P value
Male	41.0	52.7	<0.001
Age at visit (years)	12.8 [9.9–15.2]	13.2 [10.0–15.7]	<0.001
Age of diabetes diagnosis (years)	5.4 [2.9–8.7]	7.0 [4.0–10.2]	<0.001
Age <5 years at diabetes onset	45.6	32.8	<0.001
Diabetes duration at visit (years)	5.7 [3.1–9.0]	4.8 [2.5–7.8]	<0.001
Ethnic minority	15.0	18.3	<0.001
Height SDS	0.36 [−0.40 to 1.05]	0.48 [−0.23 to 1.18]	$<0.001^*$
BMI SDS	0.61 [−0.07 to 1.25]	0.67 [−0.01 to 1.36]	0.006*
Overweight/obese	34.0	37.1	$<0.001^*$
Mean HbA _{1c}			
%	8.3 ± 1.5	8.4 ± 1.6	0.052*
mmol/mol	67.4 ± 16.6	67.9 ± 17.5	0.052*
HbA _{1c}			
$<7.5\%$ (58 mmol/mol)	30.9	30.5	0.054*
$>9.0\%$ (75 mmol/mol)	24.7	26.5	0.047*
Insulin pump therapy	40.9	36.8	0.405*
Insulin dose (units/kg/day)	0.80 [0.64–1.01]	0.82 [0.65–1.02]	0.025**
Number of SMBG/day	5.5 [4.3–7.0]	5.0 [4.0–7.0]	0.016*
Severe hypoglycemia	2.5	1.8	0.094*

Data are reported as percentages, median [interquartile range], or mean \pm SD. SMBG, self-monitoring of blood glucose. *P values adjusted for age, sex, and diabetes duration. **P value adjusted for age, sex, diabetes duration, and insulin pump use.

Table 3—Characteristics of patients with CD by registry

	DPV (<i>n</i> = 785)	T1DX (<i>n</i> = 143)	NPDA (<i>n</i> = 645)	ADDN (<i>n</i> = 262)	<i>P</i> value
CD prevalence	3.2	1.9	3.8	7.7	<0.001
CD diagnosed before diabetes	6.3	3.5		2.1	0.05
CD diagnosed within 2 years of diabetes diagnosis	55.9	31.6		69.1	<0.001
Age at CD diagnosis (years)	8.1 [5.3–11.2]	8.0 [6.0–11.0]		8.0 [4.8–11.6]	0.94
Age <5 years at CD diagnosis	21.9	17.5		26.3	0.28
Diabetes duration (years)	5.2 [2.3–8.6]	6.0 [4.0–9.0]	6.4 [4.0–9.5]	5.3 [2.8–8.8]	<0.001
Male	40.9	44.8	41.5	38.2	0.62
Ethnic minority	19.5	10.5	9.6	22.0	<0.001
Insulin pump therapy	50.7	75.0	20.9	43.0	<0.001
Severe hypoglycemia	1.7	2.1		6.9	<0.001

Data are reported as percentages or median [interquartile range].

with type 1 diabetes, with an overall prevalence of 3.5%. Rates varied across the registries, from 1.9% (T1DX) to 7.7% (ADDN). The prevalence of CD was higher in girls than in boys (4.3% vs. 2.9%), and the mean age at diabetes diagnosis was lower in those with coexisting CD (5.4 vs. 7.0 years). Fewer children with coexisting CD were from minority ethnic groups compared with type 1 diabetes only (15% vs. 18%); however, this was not a consistent finding across all registries. Reassuringly, mean HbA_{1c} over the previous 12 months was not different in those with CD after adjusting for age, sex, and diabetes duration. However, it is of concern that only 31% of young people with type 1 diabetes overall achieved the international target HbA_{1c} level of <7.5% (23), irrespective of the diagnosis of CD.

The prevalence estimate for CD is slightly lower than the rate of 5.1% reported in a recent systematic review (1), although it falls within the 95% CI (3.1–7.4%). Notably, the systematic review included only longitudinal cohort studies with at least 5 years of follow-up, whereas the data in this report are cross-sectional over a 12-month period, with a median diabetes duration of 4.9 years; therefore, prevalence estimates would be expected to be lower. Furthermore, since most patients with type 1 diabetes who have coexisting CD are asymptomatic and the diagnosis of CD depends on screening practices, prevalence rates may be underestimated in some of the registries. The frequency of screening was not documented in all registries, but the positive relationship between the prevalence of

CD and the proportion of children who received a diagnosis within 2 years after the diagnosis of diabetes implies variable screening frequency.

The differences in the rates of CD may reflect our strict definition of biopsy-proven CD, which aligns with the ISPAD and American Diabetes Association guidelines (17,18,24). However, diagnostic practices vary internationally, including whether a small bowel biopsy is required for the diagnosis of CD (25,26). Two of the registries (the DPV and T1DX) additionally reported “suspected CD”; it is likely that a proportion of the 2% of patients in this category have CD. The variation in prevalence across the registries is also likely to reflect differences in CD risk, particularly given the diversity in ethnicity across the registries.

Overall, 5.4% of children received a diagnosis of CD before a diagnosis of type 1 diabetes, which is similar to the 7% of children reported in a recent systematic review (1). In cohort studies of children who are at increased risk for both conditions where serial screening is performed from birth, CD is commonly detected. For example, CD developed in 11% of children homozygous for DR3-DQ2 by age 5 years in the TEDDY study (4). Long-term follow-up of such cohorts will further our understanding of the temporal relationship between the development of type 1 diabetes and the development of CD.

In the general population, the prevalence of CD is higher in females (27). In contrast, a female sex bias was observed in only two of nine cohort studies that reported data on 587 cases of CD in patients with type 1 diabetes (1),

and several small European studies reported a male sex bias. The current study represents a much larger sample size (*n* = 1,835) and greater ethnic diversity, with a female sex bias observed in all four registries. The registry data also confirm the greater risk of CD in children who have received a diagnosis of type 1 diabetes at a young age, particularly at <5 years of age. Since more than half of CD case patients received a diagnosis within 2 years of the diagnosis of diabetes, the findings highlight the importance of recommendations to screen for CD at diagnosis and at least once within the subsequent 2 years (1,17).

CD was traditionally considered a disease predominantly affecting people of white European heritage; however, the disease is increasingly recognized in people from nonwhite ethnic groups (27–29). Although the proportion of CD case patients from nonwhite ethnic groups was slightly lower overall in this study (15% vs. 18%), subgroup analysis by registry demonstrated significant differences by ethnicity in the T1DX and ADDN. Genetic susceptibility to CD is well established, and the genetic susceptibility to both type 1 diabetes and CD shares common alleles (30,31). Our findings highlight the interplay between genetic and environmental factors in the development of CD, including the rising incidence of CD in “low risk” populations, which parallels the increase in wheat consumption globally.

The significantly lower height SDS in participants with coexisting CD is of concern and contrasts with several reports (32,33) that have found no difference in

height SDS or growth in youth with coexisting CD compared with type 1 diabetes only. However, catch-up growth and improved height SDS were reported after 1 year of adherence to the gluten-free diet in a small Italian study (34). Since dietary adherence was not documented in the four registries, it is possible that the lower height SDS may reflect a subgroup of patients who do not adhere to the gluten-free diet. Alternatively, there may be a subgroup of patients who have not achieved catch-up growth after the diagnosis of CD. Poor glycemic control can impact growth and final height in patients with type 1 diabetes (35); however, HbA_{1c} level was not worse in those with CD in the current study, suggesting that other factors influence growth in patients with CD. For example, the higher glycemic index of the gluten-free diet may contribute to greater glycemic variability. In addition, an altered dietary micronutrient composition associated with the gluten-free diet may influence growth in young people with CD.

Across the four registries, the glycemic control of young people with coexisting type 1 diabetes and CD did not differ from that of their counterparts with type 1 diabetes alone. It is reassuring that their glycemic control was not worse, given that the risk of vascular complications including retinopathy and nephropathy may be higher in patients with CD (7,36), particularly in association with nonadherence to the gluten-free diet (9).

The analysis of international registry data provides an important opportunity to compare and contrast clinical outcomes and to explore similarities and differences in clinical characteristics and therapy. Although this is a strength of the current study, which is the largest analysis of case patients with type 1 diabetes and CD to date, the cross-sectional design limits the conclusions that can be drawn from the analyses. Nevertheless, the role of benchmarking is established as a tool to improve patient care and outcomes. In particular, these data suggest variability in the screening, diagnosis, and treatment practices for CD in youth with type 1 diabetes. More data are needed to inform best practice.

The multicenter data on >50,000 youths with type 1 diabetes spanning three continents demonstrate the variable prevalence of CD but that confirm it is a common comorbidity. The findings support universal

screening for CD in patients with type 1 diabetes, particularly within the first 2 years after the diagnosis of diabetes, irrespective of ethnicity (17). Although the lower height SDS in those with CD warrants further investigation using longitudinal data and documentation of adherence to the gluten-free diet, the observation emphasizes the importance of monitoring growth and nutrition in this population.

Acknowledgments. The authors thank the thousands of patients and families who contributed to these registries/audits and the numerous investigators.

Funding. The DPV is supported through the German Federal Ministry for Education and Research within the Competence Network for Diabetes Mellitus (grant FKZ 01GI1106), which was integrated into the German Center for Diabetes Research (DZD) as of January 2015. A listing of sites contributing data for the DPV is available at <http://www.d-p-v.eu>. The T1DX is supported through The Leona M. and Harry B. Helmsley Charitable Trust. A listing of the T1DX sites is available at <https://t1dexchange.org/pages/resources/clinic-network/#4/37.16/-96.33>. The NPDA is funded by the Healthcare Quality Improvement Partnership and delivered by the Royal College of Paediatrics and Child Health. A listing of the NPDA sites in England and Wales sites contributing data is available at <http://www.rcpch.ac.uk/nationalpaediatric-diabetes-audit-npda>. The ADDN is supported by The Australian Type 1 Diabetes Clinical Research Network, led by JDRF Australia (grant 17-2011-665), the recipient of Australian Government funding from the Australian Research Council (through a Special Research Initiative) and the Department of Health and Ageing. A listing of the ADDN sites contributing data and ADDN Study Group Investigators is available at <http://addn.org.au/>. M.E.C. is a recipient of a National Health and Medical Research Council Practitioner fellowship (APP1045777).

Duality of Interest. R.W.H. holds an equity fund that may contain stock from pharmaceutical companies. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. M.E.C. researched data, performed statistical analyses, and wrote and edited the manuscript. N.P. and R.W.H. performed statistical analyses and reviewed and edited the manuscript. C.T.B., F.M.C., T.W.J., S.E.H., J.H.S., N.H., E.T., E.F.-R., S.D., H.T., D.M.M., and J.T.W. researched the data and reviewed and edited the manuscript. B.K. reviewed and edited the manuscript. The registries are represented by the following authors: M.E.C., T.W.J., E.T., and B.K. (ADDN); N.P., S.E.H., E.F.-R., and R.W.H. (DPV); C.T.B., J.H.S., S.D., and D.M.M. (T1DX); and F.M.C., N.H., H.T., and J.T.W. (NPDA). M.E.C. and R.W.H. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Pham-Short A, Donaghue KC, Ambler G, Phelan H, Twigg S, Craig ME. Screening for celiac disease in type 1 diabetes: a systematic review. *Pediatrics* 2015;136:e170–e176
2. Altobelli E, Paduano R, Petrocilli R, Di Orio F. Burden of celiac disease in Europe: a review of its childhood and adulthood prevalence and incidence as of September 2014. *Ann Ig* 2014;26:485–498
3. Bianchi M, Cartabia M, Clavenna A, et al. Serological screening for celiac disease in a northern Italian child and adolescent population after the onset of type 1 diabetes: a retrospective longitudinal study of a 7-year period. *Eur J Gastroenterol Hepatol* 2016;28:696–701
4. Liu E, Lee HS, Aronsson CA, et al.; TEDDY Study Group. Risk of pediatric celiac disease according to HLA haplotype and country. *N Engl J Med* 2014; 371:42–49
5. Gujral N, Freeman HJ, Thomson AB. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. *World J Gastroenterol* 2012;18: 6036–6059
6. Simmons KM, McFann K, Taki I, et al. Reduced bone mineral density is associated with celiac disease autoimmunity in children with type 1 diabetes. *J Pediatr* 2016;169:44–48.e1
7. Rohrer TR, Wolf J, Liptay S, et al.; DPV Initiative and the German BMBF Competence Network Diabetes Mellitus. Microvascular complications in childhood-onset type 1 diabetes and celiac disease: a multicenter longitudinal analysis of 56,514 patients from the German-Austrian DPV Database. *Diabetes Care* 2015;38:801–807
8. Taler I, Phillip M, Lebenthal Y, de Vries L, Shamir R, Shalitin S. Growth and metabolic control in patients with type 1 diabetes and celiac disease: a longitudinal observational case-control study. *Pediatr Diabetes* 2012;13:597–606
9. Pham-Short A, C Donaghue K, Ambler G, et al. Early elevation of albumin excretion rate is associated with poor gluten-free diet adherence in young people with celiac disease and diabetes. *Diabet Med* 2014;31:208–212
10. Hofer SE, Schwandt A, Holl RW; Austrian/German DPV Initiative. Standardized documentation in pediatric diabetology: experience from Austria and Germany. *J Diabetes Sci Technol* 2016;10:1042–1049
11. Warncke K, Liptay S, Fröhlich-Reiterer E, et al. Vascular risk factors in children, adolescents, and young adults with type 1 diabetes complicated by celiac disease: results from the DPV initiative. *Pediatr Diabetes* 2016;17:191–198
12. Sherr JL, Hermann JM, Campbell F, et al.; T1D Exchange Clinic Network, the DPV Initiative, and the National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health registries. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. *Diabetologia* 2016;59:87–91
13. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. *Diabetes Care* 2015;38:971–978
14. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. *J Clin Endocrinol Metab* 2012;97:4383–4389

15. Clapin H, Phelan H, Bruns L Jr, et al.; Australasian Diabetes Data Network (ADDN) Study Group. Australasian Diabetes Data Network: building a collaborative resource. *J Diabetes Sci Technol* 2016;10:1015–1026
16. Phelan H, Clapin H, Bruns L, et al. The Australasian Diabetes Data Network: first national audit of children and adolescents with type 1 diabetes. *Med J Aust* 2017;206:121–125
17. Kordonouri O, Klingensmith G, Knip M, et al.; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Other complications and diabetes-associated conditions in children and adolescents. *Pediatr Diabetes* 2014;15(Suppl. 20):270–278
18. Kordonouri O, Maguire AM, Knip M, et al. Other complications and associated conditions with diabetes in children and adolescents. *Pediatr Diabetes* 2009;10(Suppl. 12):204–210
19. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. *J Pediatr* 1994;125:177–188
20. World Health Organization. WHO reference 2007. Growth reference data for 5-19 years [article online], 2013. Available from <http://www.who.int/growthref/en/>. Accessed 25 May 2016
21. World Health Organization. Child growth standards. BMI for age [article online], 2014. Available from http://www.who.int/childgrowth/standards/bmi_for_age/en/. Accessed 25 May 2016
22. Australian Bureau of Statistics. *Australian Standard Classification of Cultural and Ethnic Groups*. Canberra, Australia Capital Territory, Australia, Australian Bureau of Statistics, 2011
23. Rewers MJ, Pillay K, de Beaufort C, et al.; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes. *Pediatr Diabetes* 2014;15(Suppl. 20):102–114
24. American Diabetes Association. Summary of revisions. In *Standards of Medical Care in Diabetes—2017*. *Diabetes Care* 2017;40(Suppl. 1):S4–S5
25. Kelly CP, Bai JC, Liu E, Leffler DA. Advances in diagnosis and management of celiac disease. *Gastroenterology* 2015;148:1175–1186
26. Husby S, Koletzko S, Korponay-Szabó IR, et al.; ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr* 2012;54:136–160
27. Kang JY, Kang AH, Green A, Gwee KA, Ho KY. Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. *Aliment Pharmacol Ther* 2013;38:226–245
28. Remes-Troche JM, Rios-Vaca A, Ramírez-Iglesias MT, et al. High prevalence of celiac disease in Mexican Mestizo adults with type 1 diabetes mellitus. *J Clin Gastroenterol* 2008;42:460–465
29. Honar N, Karamzadeh Z, Saki F. Prevalence of celiac disease in patients with type 1 diabetes mellitus in the south of Iran. *Turk J Gastroenterol* 2013;24:122–126
30. Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. *N Engl J Med* 2008;359:2767–2777
31. Gutierrez-Achury J, Romanos J, Bakker SF, et al.; Type 1 Diabetes Genetics Consortium. Contrasting the genetic background of type 1 diabetes and celiac disease autoimmunity. *Diabetes Care* 2015;38(Suppl. 2):S37–S44
32. Goh VL, Estrada DE, Lerer T, Balarezo F, Sylvester FA. Effect of gluten-free diet on growth and glycemic control in children with type 1 diabetes and asymptomatic celiac disease. *J Pediatr Endocrinol Metab* 2010;23:1169–1173
33. Sun S, Puttha R, Ghezaiel S, Skae M, Cooper C, Amin R; North West England Paediatric Diabetes Network. The effect of biopsy-positive silent coeliac disease and treatment with a gluten-free diet on growth and glycaemic control in children with Type 1 diabetes. *Diabet Med* 2009;26:1250–1254
34. Sponzilli I, Chiari G, Iovane B, et al. Celiac disease in children with type 1 diabetes: impact of gluten free diet on diabetes management. *Acta Biomed* 2010;81:165–170
35. Bonfig W, Kapellen T, Dost A, et al.; Diabetes Patienten Verlaufsdokumentationssystem Initiative of the German Working Group for Pediatric Diabetology and the German Bundesministerium für Bildung und Forschung Competence Net for Diabetes Mellitus. Growth in children and adolescents with type 1 diabetes. *J Pediatr* 2012;160:900–3.e2
36. Mollazadegan K, Kugelberg M, Montgomery SM, Sanders DS, Ludvigsson J, Ludvigsson JF. A population-based study of the risk of diabetic retinopathy in patients with type 1 diabetes and celiac disease. *Diabetes Care* 2013;36:316–321